Effect of Telmisartan on left ventricular hypertrophy and earlier period renal dysfunction in patients with essential hypertension
Haibo Yu
Abstract
Haibo Yu
Abstract
AIM: To evaluate the effect of Telmisartan on target organ damage in patients with mild to moderate hypertension. METHODS: 60 patients with mild to moderate hypertension complicated with left ventricular hypertrophy were treated with Telmisartan for 26 weeks. The IVST,LVPWT,A/E,LVMI were checked by echocardiography and the concentrations of serum β 2-MG and urine β 2-MG were determined before and after treatment. RESULTS: Both SBP and DBP decreased after the treatment of Telmisartan ,the effective rates were 72%, LVMI,A/E,serum β 2-MG and urine β 2-MG significantly decreased after Telmisartan treatment. CONCLUSION: Telmisartan was effective not only in treating of hypertension but also in preventing heart and kidney from dysfunction.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
AIM: To evaluate the effect of Telmisartan on target organ damage in patients with mild to moderate hypertension. METHODS: 60 patients with mild to moderate hypertension complicated with left ventricular hypertrophy were treated with Telmisartan for 26 weeks. The IVST,LVPWT,A/E,LVMI were checked by echocardiography and the concentrations of serum β 2-MG and urine β 2-MG were determined before and after treatment. RESULTS: Both SBP and DBP decreased after the treatment of Telmisartan ,the effective rates were 72%, LVMI,A/E,serum β 2-MG and urine β 2-MG significantly decreased after Telmisartan treatment. CONCLUSION: Telmisartan was effective not only in treating of hypertension but also in preventing heart and kidney from dysfunction.
Key concepts: Telmisartan, Medicine, Left ventricular hypertrophy, Internal medicine, Cardiology, Essential hypertension, Renal Hypertrophy, Urine